Review Article

Proteomic Approaches in Understanding Action Mechanisms of Metal-Based Anticancer Drugs

Ying Wang and Jen-Fu Chiu

Department of Anatomy, The University of Hong Kong, Pok Fu Lam Road, Hong Kong SAR, China

Correspondence should be addressed to Jen-Fu Chiu, jfchiu@hku.hk

Received 19 November 2007; Revised 20 April 2008; Accepted 17 June 2008

Recommended by Rafael Moreno-Sanchez

Medicinal inorganic chemistry has been stimulating largely by the success of the anticancer drug, cisplatin. Various metal complexes are currently used as therapeutic agents (e.g., Pt, Au, and Ru) in the treatment of malignant diseases, including several types of cancers. Understanding the mechanism of action of these metal-based drugs is for the design of more effective drugs. Proteomic approaches combined with other biochemical methods can provide comprehensive understanding of responses that are involved in metal-based anticancer drugs-induced cell death, including insights into cytotoxic effects of metal-based anticancer drugs, correlation of protein alterations to drug targets, and prediction of drug resistance and toxicity. This information, when coupled with clinical data, can provide rational bases for the future design and modification of present used metal-based anticancer drugs.

Copyright © 2008 Y. Wang and J.-F. Chiu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. METAL-BASED ANTICANCER DRUGS

Medicinal applications of metal complexes as therapeutic drugs have a more than 5000-year history [1]. Since the discovery of the anticancer activity of cisplatin by Shimizu and Rosenberg 35 years ago, there has been a rapid expansion in research to find new, more effective metal-based anticancer drugs [2]. The major classes of metal-based anticancer drugs include platinum (II), gold (I) and gold (III), metalloporphyrin, ruthenium (II) and ruthenium (III), bismuth (III), rhenium (I), and copper (II) compounds.

1.1. Platinum(II) anticancer drugs

Cisplatin represents one of the most potent drugs available in the cancer chemotherapy for several solid tumors, such as testicular, ovarian, bladder, and neck cancers [3]. It is generally believed that cisplatin exhibited its anticancer effects through preferentially binding to quinine N-7 of DNA, and then cause DNA damage specifically in cancer cells, subsequently leading to cell death [4]. After successes achieved with platinum complexes, there is a tremendous increase in the search for platinum complexes with different ligands that might produce more specific anticancer effects. Some of these platinum-based drugs have been approved by the Food and Drug Administration (FDA), including carboplatin for the treatment of ovarian cancer [5, 6], oxaliplatin for metastatic colorectal cancer [7, 8], satraplatin for hormone-refractory prostate cancer [9], and picoplatin for small-cell lung cancer [10].

Transplatinum compounds follow different patterns of cell killing in comparison to cisplatinum, thus giving a reason for optimism in their development as a new class of platinum-based anticancer drugs [11]. The initial report of anticancer properties of a dinuclear platinum complex in 1988 started a new paradigm in platinum-based chemotherapy. Several multinuclear platinum complexes have entered clinical trials in recent years, with varying results [12, 13]. The major limitations of cisplatin and other platinum anticancer drugs are related to drug resistance and their side effects, including nephrotoxicity, neurotoxicity, and emetogenesis [14]. Resistance to cisplatin is multifactorial, most cases consist of mechanisms limiting the formation of DNA adducts or operating downstream of the cisplatin-DNA interaction to promote cell survival [15].
1.2. Gold (I) and gold (III) anticancer complexes

Gold (I) complexes had been used for the treatment of arthritis some decades ago, but most of them disappeared from the drug market because of intolerable side effects, such as gastrointestinal adverse reactions, nephrotoxicity, and haematological reactions. However, the design and testing of gold complexes, especially gold (III) complexes with anticancer activity begin to be intensively pursued in the past few years. The potential use of gold (III) complexes as anticancer drugs were based on three rationales [16–18]: (a) analogies between square planar complexes of both platinum (II) and gold (III) are d8 ions; (b) analogy to the immunomodulatory effects of gold (I) antiarthritis agents; and (c) complexation of gold (I) and gold (III) with known anticancer agents to form new compounds with enhanced activity. Buckley et al. first reported some organogold (III) complexes endowed with significant cytotoxic and anticancer properties [19]. During the past decades, various gold (III) complexes with sufficient stability in the physiological environment have been synthesized and evaluated for in vitro anticancer properties. Some of these gold (III) complexes turned out to exhibit relevant cytotoxic effects in vitro and were the subject of further biochemical and pharmacological investigations [20–33]. Our previous findings showed that gold (III) mesotetraarylporphyrin 1a was stable against demetallation in physiological conditions and exhibited higher cytotoxicity than cisplatin against a panel of human cancer cell lines [34–37]. The major limitation of gold (III) complexes is that few exhibit good stability under physiological conditions, due to the reduction of gold (III) to gold (I) [38]. However, low cisplatin cross resistance has been observed in gold complexes [39]. There is therefore considerable interest in the development of tumor-selective and stable gold anticancer drugs.

1.3. Metalloporphyrin drugs

Metalloporphyrin drugs are new class of antioxidant enzyme mimetics with novel structure; a metal in the center of porphyrin ligand. Metalloporphyrins (e.g., MnTBAP) have previously been used to inhibit age-related oxidative damage in myocardium of mice that are lacking mitochondrial enzyme manganese superoxide dismutase [40]. Afterwards, metalloporphyrin drugs began to be used as photodynamic therapy agents for certain solid tumors [41]. Photodynamic therapy is based on the concept that porphyrins are known to be rapidly and preferentially taken up by the tumor cells with higher intakes of lipoproteins [42, 43]. When such photosensitizers are irradiated with an appropriate wavelength of visible or near infrared (NIR) light, the excited molecules can transfer their energy to molecular oxygen in the surroundings, which is normally in its triplet ground state. This results in the formation of cytotoxic reactive oxygen species (ROSs), particularly singlet oxygen [44]. ROSs are responsible for oxidizing various cellular compartments including plasma, mitochondrial, lysosomal, and nuclear membranes, resulting in irreversible damage of tumor [34, 44]. Therefore, under appropriate conditions, photodynamic therapy offers the advantage of an effective and selective method of destroying diseased tissues without damaging adjacent healthy cells [42, 43].

Since the approval of Photofrin by FDA for chemotherapy [45], porphyrin derivaties with different metal in the center of the molecule have been widely used as photosensitizers for photodynamic therapy in the treatment of cancer, including chlorophyllin copper complex as superoxide dismutase mimics [46, 47], FeTBAP and MnTBAP [48, 49], ZnTBAP [50], motexafin gadolinium (MGd) [51]. Different modes of actions have been suggested for different kinds of metalloporphyrins. For example, MGd has been shown to inhibit heme oxygenase-1 (HO-1) activity that results in inactivation of the antiapoptotic properties of the products of HO-1 [51]. While FeTBAP and MnTBAP have been reported to be superoxide anion scavengers [48]. MGd is also an active inhibitor of cytochrome P450 enzymes, although with a lower potency than that exhibited for inhibition of HO-1.

1.4. Other metal-based anticancer drugs

In recent years, other approaches in the search for new, metal-based anticancer agents are to examine complexes that contain other transition metals. In the design of these new drugs, octahedral ruthenium (II) and ruthenium (III) complexes have shown antineoplastic properties on a number of experimental tumors. Tetraammine-, pentaammine-, heterocycle-, and dimethylsulfoxide-coordinated ruthenium complexes have been synthesized and shown high affinity for nitrogen donor ligands in vitro and as a result exhibit anticancer action in vivo [52–54]. Other transition metals have been used as anticancer drugs, including bismuth (III) labeled antibodies for systemic radioimmunotherapy [55, 56], rhenium (I) complexes as DNA-binding agents [57], (MTR)2Zn2+ complex that induces cancer cell death by binding to chromatin [58], and Cu2+ compound chlorophyllin initiated apoptosis in human colon cancer cells through caspase-8 and apoptosis-inducing factor (AIF) activation in a cytochrome c-independent manner [46].

2. PROTEOMICS

2.1. Introduction to proteomics

The proteome is defined as all expressed protein complement of a cell, organ or organism, and it includes all isoforms and posttranslational variants. Proteomic technology, first coined in 1995 [59], attempts to separate, identify, and characterize a global set of proteins in an effort to provide information about protein abundance, location, modification, and protein-protein interaction in the proteome of a given biological system [59, 60]. This postgenomic technology provides a direct measurement of the presence and relative abundance of proteins, and reveals the consequence of protein functioning in establishing the biological phenotype of organisms in different states. By studying interrelationships of protein expressions and modifications in health and disease or drug treatment, proteomics contributes important
insights into determining the pathophysiological basis of disease [61], validating drug targets [62], and illustrating drug action [63], toxicity, and side effects [64].

2.2. Technological platforms

In the field of proteomics, several well-established methods persist as means to resolve and analyze complex mixtures of proteins derived from cells and tissues. Currently, the most commonly used proteomic platforms include two-dimensional gel electrophoresis (2DE) and protein chip arrays, isotope-coded affinity tags (ICATs), and immobilized metal affinity chromatography (IMAC) (Table 1). These technological platforms are most often incorporated with matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) [65], surface enhanced laser desorption ionization time of flight (SELDI-TOF) [66], electrospray ionization (ESI) [67], and/or tandem mass spectrometry (MS/MS). In addition, inductively coupled plasma (ICP) mass spectrometry has also been applied in proteomic-based research of drug discovery [68].

3. POTENTIAL APPLICATIONS OF PROTEOMICS IN ILLUSTRATING METAL-BASED DRUG DEVELOPMENT AND DISCOVERY

Ever since the initial discovery of the anticancer activity of cisplatin, major efforts have been devoted to elucidate the biochemical mechanisms of anticancer activities of metal-based drugs to facilitate rational design of novel metal-based drugs with better pharmacological profiles. A comprehensive understanding of the molecular action mechanisms, which are triggered by metal-based drugs to kill cancer cells, can lead to the design of more effective anticancer drugs, as well as to provide new therapeutic strategies based on the molecular activity of metal-based drug activity.

3.1. Target discovery and validation

Target discovery, which involves the identification and early validation of disease-associated targets, is an essential first step in the drug discovery pipeline [81]. Indeed, the drive to determine protein function has been stimulated, both in industry and academia, by the human genome and proteome projects in progress. Proteomics, the study of cellular protein expression, is an evolving technology platform that has the potential to identify novel proteins involved in key biological processes in cells. These proteins may serve as potential drug targets. Proteomics thus holds great promise as a powerful technique for drug target discovery. It must be pointed out, however, that numerous drug-targeted proteins are membrane-bound proteins, for example, receptors and ion channels. These proteins may not be amenable for study by proteomics due to their poor solubility and low abundance, and thus they are disproportionately represented in proteome profiles [82]. Up to date, only a fraction of putative drug targets has been identified by proteomic approaches, including the volume-sensitive organic osmolyte/anion channel as key elements of tumor development, migration, and invasiveness [83], and integrin alpha-4 as a molecular target of oxidative stress [84].

Studying protein expression profiling of drug-treatment leads to the identification of a number of drug-specific targets both in vivo and in vitro. Using HPLC-MALDI-TOF MS, Hasinoff et al. have identified topoisomerase IIA contained at least five free cysteins (170, 216, 300, 392, and 405) and two disulfide-bonded cysteine pairs (427-455 and 997-1008) [85]. Cisplatin was found to antagonize the formation of a fluorescence adduct between topoisomeraser IIA and the sulfhydryl-reactive maleimide reagent 10-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-9-methoxy-3-oxo-3H-naphtho[2,1-b]pyran-2-carboxylic acid methyl ester (ThioGlo-1). Based on these results, the authors suggested that topoisomeraser IIA cysteines may be possible sites responsible for the inhibition of the catalytic activity of topoisomeraser IIA observed in the presence of cisplatin, and topoisomeraser IIA cysteine and DNA as targets responsible for cisplatin-induced inhibition of topoisomeraser IIA [85]. Besides, mitochondrial proteins, especially ATP synthase-beta subunit, have been reported to be key proteins that serve as primary target of manganese porphyrin [MnTnHex-2-PyP(5+)] treatment during renal ischemia/reperfusion injury by proteomic study [86].

ICP MS coupled with capillary electrophoresis (CE) has been used in the identification, characterization, and determination of different chemical species of an element in complex biological systems, that is, the impetus of biochemical speciation analysis [87, 88]. Polec-Pawlak et al. have used this approach to study the platinum group metalloprotein-protein binding aiming to characterize the interactions between cancer-inhibiting metal complexes and serum transport proteins [89]. Such binding does not only regulate the uptake and accumulation of the drug in tumor tissue but also determines its overall distribution and exertion and differences in efficacy, activity, and toxicity [90, 91]. Their study provides clear evidence that a ruthenium (III) complex [trans-tetrachlorobis(1H-indazole)ruthenate (III)] (KP1019) preferentially binds toward albumin whose adduct is a dominating protein-bound species of ruthenium [89].

3.2. Validation of drug toxicity and resistance

Insights into toxic responses are an asset for the interpretation of adverse drug effects and contribution to accurate risk assessment for humans. Proteomics in combination with combinatorial chemistry and high-throughput screening can help to bring forward validating toxicity and resistance of an unprecedented number of potential lead compounds [92]. Benefits can be expected in optimized clinical trials based on the availability of biologically relevant markers of drug efficacy and safety. Proteomics has demonstrated proof-of-concept in toxicology as shown by a number of successful applications in mechanistic toxicology and lead selection. Proteomic studies of liver toxicity have been carried out with thioacetamide [93] and ethanol [64]. Other researches have studied nephrotoxicity of cyclosporine A by proteomic approaches [94, 95] and reported a profound
downregulation of the calcium binding protein calbindin D28 responsible for cyclosporine A-induced kidney toxicity. However, this technology-driven acceleration in drug discovery moves the bottlenecks in drug development to the downstream, which is the improvement in the selection of patient populations for clinical trials.

Proteomic approaches have been used to identify the underlying mechanisms for cisplatin resistance [96]. In this study, the authors used cervix squamous cell carcinoma cell line A431 and its cisplatin-resistant subline, A431/Pt as model system. The identified differentially expressed proteins can be classified into several groups, including molecular chaperones (e.g., heat-shock protein HSP60, HSP90, and HSC71), Ca<sup>2+</sup>-binding proteins (e.g., calmodulin and calumenin), proteins involved in drug detoxification (e.g., peroxiredoxin 2 and 6, and glutathione-S-transferase), antiapoptotic proteins (e.g., 14-3-3 switched on in cisplatin-exposed cells) and ion channels (e.g., voltage-dependent anion channel 1, voltage-dependent anion-selective channel). Besides this, proteome profile of cisplatin sensitive ovarian cell line IGROV1 and its cisplatin-resistant counterpart IGROV1-R10 have been compared aiming to find any protein markers or to establish new therapeutic strategies [97, 98]. Increased expression of cytokeratin 8 and cytokeratin 18 was considered to play a role in acquired chemoresistance of IGROV1-R10 cancer cell line to cisplatin [97, 98]. Cytokeratin 8 and cytokeratin 18 have been implicated in resistance to TNF-α-induced apoptosis by binding the cytoplasmic domain of tumor necrosis factor receptor 1 [69, 99]. Moreover, human nasopharyngeal carcinoma cells deficient for cytokeratin 8 were more sensitive to cisplatin-induced apoptosis [100].

In addition, acquired and intrinsic cellular drug resistances are multifactorial processes, involving induction of drug detoxifying mechanisms, quantitative and qualitative modification of drug targets, cell cycle arrest, regulation of DNA replication or reparation mechanisms, modulation of apoptosis, and other mechanisms [101, 102]. Global examination of the glycoproteomes of the cisplatin-resistant ovarian cancer cell line IGROV-1/CP using shotgun glycopeptide capture approach coupled with MS has been used to study cisplatin resistance [103]. In this approach, glycopeptides derived from glycoproteins are enriched by selective capture onto a solid support using hydrazide chemistry followed by enzymatic release of the peptides and subsequent analysis by MS/MS. This method improves solubility of large membrane proteins and exposes all of the glycosylation sites to ensure equal accessibility to capture reagents. Stewart et al. also used isotope-coded affinity tags (ICATs) integrated with mRNA expression levels to study cisplatin resistance in ovarian cancer cells [104]. Their study identified three pathways in Panther database (http://www.pantherdb.org/) that were

### Table 1: Major technological platforms in proteomics.

| Technique | 2DE (Two-dimensional gel electrophoresis) | SELDI-TOF MS | ICAT (Isotope-coded affinity tags) | IMAC (Immobilized metal affinity chromatography) |
|-----------|------------------------------------------|--------------|----------------------------------|-----------------------------------------------|
| Principles | 2DE separates protein mixtures by their isoelectric points and molecular weights, proteins can be identified by MALDI-TOF MS through enzyme digestion | This technique employs protein chip separates protein mixtures by different surface binding affinity and molecular weights, and roughly identifies proteins through SELDI-TOF MS | ICAT separates proteins by chemical labeling and relative abundance, and then obtains protein identification through ESI MS/MS | IMAC is a powerful protein fractionation method used to enrich metal-associated proteins and peptides, proteins and peptides can be determined by ESI MS/MS |
| Remarks | Suitable for whole proteome or specific pre-fractioned proteomes, detect large quantity of proteins in a single run, not suitable for low abundant proteins, affected by posttranslational modifications | Simple preparation procedures, sensitive detection limit, small sample requirement, significant results, wide detection range in molecular weight, modified by different surface affinities | Biotinylated tags labeling before analysis; suitable for low abundant proteins; not suitable for post translational modified proteins; more automated | Enrich metal-associated proteins and peptides, easy regeneration, longevity and stability to proteolytic degradation, have to be facilitated by other separation methods, suitable for posttranslational modification |
| Potential applications | Study drug-induced cellular signaling pathway in a global scale [35, 69] | Identification of drug targets [70] | Receptome profiling [75, 76] | Mapping of phosphoproteomes [77, 78] and metalloproteomes [79, 80] |
| | Identification of drug targets [70] | Screen drug candidates [72, 73] | |
| | Study of drug toxicity and side effects [71] | Study of protein-drug interactions [74] | |
significantly ($p < 0.05$) upregulated in cisplatin-sensitive cells, including glycolysis, interleukin signaling pathway, and PI 3-kinase pathway [104].

3.3. Mapping drug action mechanisms

An understanding of protein function within the context of complex cellular networks is required to facilitate the discovery of novel drug targets and, subsequently, new therapies directed against them. Proteomics offers comprehensive monitoring of protein alterations at molecular level upon drug treatments. Being the basic biochemical mode of drug activities, drug action mechanism should be better understood to provide valuable insights into drug modification and new drug development [34, 105]. Successful examples in drug mechanism study using proteomics include the illustration of insulin-like growth factor-binding protein-6-induced sublethal hydrogen peroxide stress in human diploid fibroblasts cells [106]. By using ESI MS/MS, Kanski et al. have applied proteomic analysis of protein nitration in aging skeletal muscle and identified nitrotyrosine-containing sequences in vivo [107].

In our previous study, we have used 2DE-based proteomic technology to compare the protein profile of human nasopharyngeal carcinaoma SUNE1 cell line treated with gold (III) porphyrin 1a, and a number of differentially expressed proteins were identified [35]. These proteins can be classified into several categories based on their major biological functions, including cellular structural proteins, stress-related and chaperone proteins, proteins involved in ROS, enzyme proteins and translation factors, proteins that mediate cell death and survival signaling, and proteins that participate in the internal degradation system [35]. Among these proteins, one of the significant increased proteins is voltage-dependent anion channel 1 (VDAC 1). VDAC 1 is a mitochondrial outer membrane channel protein, which functions as the pathway for the movement of various substances in and out of the mitochondria [108]. It is considered to be a component of the permeability transition pore oligoprotein complex that plays a role in the permeability transition [109, 110]. VDAC 1 also plays an essential role in Bax/Bak-induced apoptotic mitochondrial changes in the process of mammalian cell death [111–113]. In this process, the proapopptotic proteins Bax and Bak bind to VDAC 1, and enhance its permeability so that cytochrome c passes through the channel and releases to cytoplasm [111–113]. Our data on VDAC 1 upregulation [35] and Bax overexpression [37] suggest that gold (III) porphyrin 1a may induce cell death via the mitochondria-mediated apoptosis pathway. Further functional studies revealed that gold (III) porphyrin 1a caused depletion of mitochondrial transmembrane potential ($\Delta W_m$) soon after uptake with suppression of Bcl-2, and activation of caspase 9 and caspase 3 [34]. Taken together, these results suggested that mitochondria are the primary target of gold (III) porphyrin 1a.

Quantitative proteomic analysis on other metal-based anticancer drugs has also been pursued. Schmidt et al. have used nano-LC coupled offline MALDI-TOF/TOF-MS to study cisplatin-induced apoptosis in Jurkat T cells [114]. Their results showed that this method is more accurate than the commonly used online LC-ESI-MS.

4. CONCLUSION AND FUTURE PROSPECTS

The potential value of proteomics in metal-based drug development, especially in mapping drug action mechanisms, has been demonstrated in many successful examples. Proteomic approaches have been recognized as promising techniques that can facilitate the systematic characterization of a drug targets’ physiology, thereby helping to reduce the typically high attrition rates in discovery projects, and improving the overall efficiency of pharmaceutical research processes. However, at present stage, the bottleneck for taking full advantage of this new experimental technology is the rapidly growing volumes of automatically produced biological data, and technical challenges with regards to sampling, tumor heterogeneity, and lack of standardized methodologies. In addition, to complement the limitation of current proteomic technology, systematic biological and pharmaceutical studies should be integrated with proteomics to better serve the purpose of illustrating the action mechanism of drugs and thus contribute to the success in metal-based drug development.

ACKNOWLEDGMENT

This work was partially supported by Hong Kong Research Grants Council Grants HKU 7395/03M (to J. F. Chiu).

REFERENCES

[1] C. Orvig and M. J. Abrams, “Medicinal inorganic chemistry: introduction,” *Chemical Reviews*, vol. 99, no. 9, pp. 2201–2204, 1999.
[2] M. Shimizu and B. Rosenberg, “A similar action to UV irradiation and a preferential inhibition of DNA synthesis in *E. coli* by antitumor platinum compounds,” *Journal of Antibiotics*, vol. 26, no. 4, pp. 243–245, 1973.
[3] R. Von Roemeling, “The therapeutic index of cytotoxic chemotherapy depends upon circadian drug timing,” *Annals of the New York Academy of Sciences*, vol. 618, pp. 292–311, 1991.
[4] F. Boudsocq, P. Benaim, Y. Canitrot, et al., “Modulation of cellular response to cisplatin by a novel inhibitor of DNA polymerase β,” *Molecular Pharmacology*, vol. 67, no. 5, pp. 1485–1492, 2005.
[5] G. A. Curt, J. J. Grygiel, B. J. Corden, et al., “A Phase I and pharmacokinetic study of diamminecyclobutanedicarboxylato-platinum (NSC 241240),” *Cancer Research*, vol. 43, no. 9, pp. 4470–4473, 1983.
[6] E. Boven, W. J. F. van der Vlijgh, M. M. Nauta, H. M. M. Schlüper, and H. M. Pinedo, “Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts,” *Cancer Research*, vol. 45, no. 1, pp. 86–90, 1985.
[7] H. Ulrich-Pur, W. C. C. Fiebig, B. Schüll, G. V. Kornek, W. Scheithauer, and M. Raderer, “Oxaliplatin-induced fever and release of IL-6,” *Oncology*, vol. 59, no. 3, pp. 187–189, 2000.
[8] M. Hejna, W. J. Kostler, M. Raderer, et al., “Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in
patients with advanced or metastatic colorectal cancer,” Anti-Cancer Drugs, vol. 11, no. 8, pp. 629–634, 2000.

[9] T. Latif, L. Wood, C. Connell, et al., “Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC),” Investigational New Drugs, vol. 23, no. 1, pp. 79–84, 2005.

[10] L. Kelland, “Broadening the clinical use of platinum drug-based chemotherapy with new analogues: satraplatin and picoplatin,” Expert Opinion on Investigational Drugs, vol. 16, no. 7, pp. 1009–1021, 2007.

[11] S. Radulovic, Z. Tesis, and S. Manic, “Trans-platinum complexes as anticancer drugs: recent developments and future prospects,” Current Medicinal Chemistry, vol. 9, no. 17, pp. 1611–1618, 2002.

[12] N. J. Wheate and J. G. Collins, “Multi-nuclear platinum drugs: a new paradigm in chemotherapy,” Current Medicinal Chemistry: Anti-Cancer Agents, vol. 5, no. 3, pp. 267–279, 2005.

[13] H.-L. Chan, D.-L. Ma, M. Yang, and C.-M. Che, “Bis-intercalative dinuclear platinum(II) 6-phenyl-2,2′-bipyridine complexes exhibit enhanced DNA affinity but similar cytotoxicity compared to the mononuclear unit,” Journal of Biological Inorganic Chemistry, vol. 8, no. 7, pp. 761–769, 2003.

[14] E. Wong and C. M. Giandornenico, “Current status of platinum-based antitumor drugs,” Chemical Reviews, vol. 99, no. 9, pp. 2451–2466, 1999.

[15] R. E. Aird, J. Cummings, A. A. Ritchie, et al., “In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer,” British Journal of Cancer, vol. 86, no. 10, pp. 1652–1657, 2002.

[16] I. Haiduc and C. Silvestru, “Rhodium, iridium, copper and gold antitumor organometallic compounds (review),” In Vivo, vol. 3, no. 4, pp. 285–293, 1989.

[17] P. J. Sadler, M. Nasr, and V. L. Narayanan, “The design of metal complexes as anticancer drugs,” in Platinum Coordination Complexes in Cancer Chemotherapy, M. P. Hacker, E. B. Double, and I. H. Krakoff, Eds., pp. 290–304, Martinus Nijhoff, Boston, Mass, USA, 1984.

[18] C. F. Shaw III, “Ruthenium compound in cancer therapy,” in Metal Compounds in Cancer Therapy, S. P. Fricker, Ed., Chapman & Hall, London, UK, 1994.

[19] R. G. Buckley, A. M. Elsome, S. P. Fricker, et al., “Antitumor properties of some 2-[(dimethylamino)methyl] phenylgold(III) complexes,” Journal of Medicinal Chemistry, vol. 39, no. 26, pp. 5208–5214, 1996.

[20] A. Casini, M. A. Cinellu, G. Minghetti, et al., “Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands,” Journal of Medicinal Chemistry, vol. 49, no. 18, pp. 5524–5531, 2006.

[21] M. Coronnello, E. Mini, B. Caciglai, et al., “Mechanisms of cytotoxicity of selected organogold(III) compounds,” Journal of Medicinal Chemistry, vol. 48, no. 21, pp. 6761–6765, 2005.

[22] L. Giovagnini, L. Ronconi, D. Aldinucci, D. Lorenzon, S. Sitran, and D. Fregon, “Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosinedithiocarbamate complexes,” Journal of Medicinal Chemistry, vol. 48, no. 5, pp. 1588–1595, 2005.
[37] Y. Wang, Q.-Y. He, R. W.-Y. Sun, C.-M. Che, and J.-F. Chiu, “Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead,” European Journal of Pharmacology, vol. 554, no. 2–3, pp. 113–122, 2007.

[38] C. F. Shaw III, “Gold-based therapeutic agents,” Chemical Reviews, vol. 99, no. 9, pp. 2589–2600, 1999.

[39] C. X. Zhang and S. J. Lippard, “New metal complexes as potential therapeutic agents,” Current Opinion in Chemical Biology, vol. 7, no. 4, pp. 481–489, 2003.

[40] S. Melov, J. A. Schneider, B. J. Day, et al., “A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase,” Nature Genetics, vol. 18, no. 2, pp. 159–163, 1998.

[41] T. J. Dougherty, “An update on photodynamic therapy applications,” Journal of Clinical Laser Medicine and Surgery, vol. 20, no. 1, pp. 3–7, 2002.

[42] G. N. Georgiou, M. T. Ahmet, J. Silver, and R. J. Cherry, “Measurement of the rate of uptake and subcellular localization of porphyrins in cells using fluorescence digital imaging microscopy,” Photochemistry and Photobiology, vol. 59, no. 4, pp. 419–422, 1994.

[43] A. Villanueva and G. Jori, “Pharmacokinetic and tumour-photonsensitizing properties of the cationic porphyrin mesotetra(4N-methylpyridyl)porphine,” Cancer Letters, vol. 73, no. 1, pp. 59–64, 1993.

[44] T. J. Dougherty, C. J. Gomer, B. W. Henderson, et al., “Photodynamic therapy,” Journal of the National Cancer Institute, vol. 90, no. 12, pp. 889–905, 1998.

[45] D. A. Bellnier, W. R. Greco, G. M. Loewen, et al., “Population pharmacokinetics of the photodynamic therapy agent 2-[[hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients,” Cancer Research, vol. 63, no. 8, pp. 1806–1813, 2003.

[46] G. D. Díaz, Q. Li, and R. H. Dashwood, “Caspase-8 and apoptosis-inducing factor mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin,” Cancer Research, vol. 63, no. 6, pp. 1254–1261, 2003.

[47] S. Chernomorsky, R. Rancourt, K. Virdi, A. Segelman, and R. D. Poretz, “Antimitagencity, cytotoxicity and composition of chlorophyllin copper complex,” Cancer Letters, vol. 120, no. 2, pp. 141–147, 1997.

[48] E. A. Konorev, S. Kotamraju, H. Zhao, S. Kalivendi, J. Joseph, and B. Kalyanaraman, “Paradoxical effects of metalloporphyrins on doxorubicin-induced apoptosis: scavenging of reactive oxygen species versus induction of heme oxygenase-1,” Free Radical Biology & Medicine, vol. 33, no. 7, pp. 988–997, 2002.

[49] B. Zingarelli, B. J. Day, J. D. Crapo, A. L. Salzman, and C. Szabó, “The potential role of peroxynitrite in the vascular contractile and cellular energetic failure in endotoxic shock,” British Journal of Pharmacology, vol. 120, no. 2, pp. 259–267, 1997.

[50] J. Fang, T. Sawa, T. Akaike, K. Greish, and H. Maeda, “Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin,” International Journal of Cancer, vol. 109, no. 1, pp. 1–8, 2004.

[51] J. P. Evans, F. Xu, M. Sirisawad, R. Miller, L. Naumovski, and P. R. Ortiz de Montellano, “Motexafin gadolinium-induced cell death correlates with heme oxygenase-1 expression and inhibition of P450 reductase-dependent activities,” Molecular Pharmacology, vol. 71, no. 1, pp. 193–200, 2007.

[52] E. Reisner, V. B. Arion, M. F. C. Guedes da Silva, et al., “Tuning of redox potentials for the design of ruthenium anticancer drugs—an electrochemical study of [trans-RuCl4 L(DMSO)] and [trans-RuCl4-L2] complexes, where L = imidazole, 1,2,4-triazole, indazole,” Inorganic Chemistry, vol. 43, no. 22, pp. 7083–7093, 2004.

[53] M. J. Clarke, S. Bitler, D. Rennert, M. Buchbinder, and A. D. Kelman, “Reduction and subsequent binding of ruthenium ions catalyzed by subcellular components,” Journal of Inorganic Biochemistry, vol. 12, no. 1, pp. 79–87, 1980.

[54] L. Mishra, R. Sinha, H. Itokawa, et al., “Anti-HIV and cytotoxic activities of Ru(II)/Ru(III) polyppyridyl complexes containing 2,6-(2′-benzimidazolyl)-pyridine/chalcone as coligand,” Bioorganic & Medicinal Chemistry, vol. 9, no. 7, pp. 1667–1671, 2001.

[55] J. Kotzerke, D. Bunjes, and D. A. Scheinberg, “Radioimmunoconjugates in acute leukemia treatment: the future is radiant,” Bone Marrow Transplantation, vol. 36, no. 12, pp. 1021–1026, 2005.

[56] P. L. Beaufmer, P. Venkatesan, J.-L. Vanderheyden, et al., “186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice,” Cancer Research, vol. 51, no. 2, pp. 676–681, 1991.

[57] D.-L. Ma, C.-M. Che, F.-M. Siu, M. Yang, and K.-Y. Wong, “DNA binding and cytotoxicity of ruthenium(II) and rhenium(I) complexes of 2-amino-4-phenylamino-6-(2-pyridyl)-1,3,5-triazine,” Inorganic Chemistry, vol. 46, no. 3, pp. 740–749, 2007.

[58] S. Das and D. Dasgupta, “Binding of (MTR)_2Zn^2+ complex to chromatin: a comparison with (MTR)_2Mg^2+ complex,” Journal of Inorganic Biochemistry, vol. 99, no. 3, pp. 707–715, 2005.

[59] Q.-Y. He and J.-F. Chiu, “Proteomics in biomarker discovery and drug development,” Journal of Cellular Biochemistry, vol. 89, no. 5, pp. 868–886, 2003.

[60] R. B. Stoughton and S. H. Friend, “How molecular profiling could revolutionize drug discovery,” Nature Reviews Drug Discovery, vol. 4, no. 4, pp. 345–350, 2005.

[61] S. Hanash, “Disease proteomics,” Nature, vol. 422, no. 6928, pp. 226–232, 2003.

[62] J. Rosamond and A. Allsop, “Harnessing the power of the genome in the search for new antibiotics,” Science, vol. 287, no. 5460, pp. 1973–1976, 2000.

[63] P. R. Graves, J. J. Kwiek, P. Fadden, et al., “Discovery of novel targets of quinoline drugs in the human purine binding proteome,” Molecular Pharmacology, vol. 62, no. 6, pp. 1364–1372, 2002.

[64] A. Venkatraman, A. Landar, A. J. Davis, et al., “Modification of the mitochondrial proteome in response to the stress of ethanol-dependent hepatotoxicity,” Journal of Biological Chemistry, vol. 279, no. 21, pp. 22092–22101, 2004.

[65] D. J. Harvey, “Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update covering the period 2001-2002,” Mass Spectrometry Reviews, vol. 27, no. 2, pp. 125–201, 2008.

[66] X. Jiang, M. Ye, and H. Zou, “Technologies and methods for sample pretreatment in efficient proteome and peptide analysis,” Proteomics, vol. 8, no. 4, pp. 686–705, 2008.

[67] H. Oberacher and W. Parson, “Forensic DNA fingerprinting by liquid chromatography-electrospray ionization mass spectrometry,” BioTechniques, vol. 43, no. 4, pp. vii–xiii, 2007.

[68] A. A. Ammann, “Inductively coupled plasma mass spectrometry (ICP MS): a versatile tool,” Journal of Mass Spectrometry, vol. 42, no. 4, pp. 419–427, 2007.
[69] A. T. Y. Lau and J.-F. Chiu, “The possible role of cytokeratin 8 in cadmium-induced adaptation and carcinogenesis,” Cancer Research, vol. 67, no. 5, pp. 2107–2113, 2007.

[70] G. Sjoholt, N. Anensen, L. Wergeland, E. M. Cormack, O. Bruserud, and B. T. Gjertsen, “Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy,” Current Drug Targets, vol. 6, no. 6, pp. 631–646, 2005.

[71] K. Godl, O. J. Gruss, J. Eickhoff, et al., “Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling,” Cancer Research, vol. 65, no. 15, pp. 6919–6926, 2005.

[72] R. Papoian, A. Scherer, M. Saulnier, et al., “VeloceGenomics: an accelerated in vivo drug discovery approach to rapidly predict the biologic, drug-like activity of compounds, proteins, or genes,” Pharmaceutical Research, vol. 22, no. 10, pp. 1597–1613, 2005.

[73] J. Huang, H. Zhu, S. J. Haggarty, et al., “Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 47, pp. 16594–16599, 2004.

[74] Y. Xu, J. Shi, N. Yamamoto, J. A. Moss, P. K. Vogt, and K. D. Janda, “A credit-card library approach for disrupting protein-protein interactions,” Bioorganic & Medicinal Chemistry, vol. 14, no. 8, pp. 2660–2673, 2006.

[75] M. Asano, T. Nakajima, K. Iwasawa, et al., “Inhibitory effects of ω-3 polyunsaturated fatty acids on receptor-mediated non-selective cation currents in rat A7r5 vascular smooth muscle cells,” British Journal of Pharmacology, vol. 120, no. 7, pp. 1367–1375, 1997.

[76] A. V. Zhlos and T. B. Bolton, “Effects of protons on muscarinic receptor cationic current in single visceral smooth muscle cells,” American Journal of Physiology, vol. 272, no. 2, pp. G215–G223, 1997.

[77] M. C. Posewitz and P. Tempst, “Immobilized gallium(III) affinity chromatography of phosphopeptides,” Analytical Chemistry, vol. 71, no. 14, pp. 2883–2892, 1999.

[78] T. S. Nühse, A. Stensballe, O. N. Jensen, and S. C. Peck, “Large-scale analysis of in vivo phosphorylated membrane proteins by immobilized metal ion affinity chromatography and mass spectrometry,” Molecular & Cellular Proteomics, vol. 2, no. 11, pp. 1234–1243, 2003.

[79] P. Junghut, H. Baumeister, and J. Klose, “Classification of mouse liver proteins by immobilized metal affinity chromatography and two-dimensional electrophoresis,” Electrophoresis, vol. 14, no. 7, pp. 638–643, 1993.

[80] X. Yu, M. Wojciechowski, and C. Fenselau, “Assessment of metals in reconstituted metallothioneins by electrospay mass spectrometry,” Analytical Chemistry, vol. 65, no. 10, pp. 1355–1359, 1993.

[81] Y. Wang, J.-F. Chiu, and Q.-Y. He, “Proteomics in computer-aided drug design,” Current Computer: Aided Drug Design, vol. 1, no. 1, pp. 43–52, 2005.

[82] C. Smith, “Drug target identification: a question of biology,” Nature, vol. 428, no. 6979, pp. 225–231, 2004.

[83] A. R. L. Davies, M. J. Belsey, and R. Z. Kozlowski, “Volumetric sensitive organic osmolyte/anion channels in cancer: novel approaches to studying channel modulation employing proteomics technologies,” Annals of the New York Academy of Sciences, vol. 1028, pp. 38–55, 2004.

[84] T. Laragione, V. Bonetto, F. Casoni, et al., “Redox regulation of surface protein thiol: identification of integrin α-4 as a molecular target by using redox proteomics,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 14737–14741, 2003.

[85] B. B. Hasinoff, X. Wu, O. V. Krokhin, et al., “Biochemical and proteomics approaches to characterize topoisomerase IIα cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIα,” Molecular Pharmacology, vol. 67, no. 3, pp. 937–947, 2005.

[86] H. Saba, I. Batinich-Haberle, S. Munusamy, et al., “Manganese porphyrin reduces renal injury and mitochondrial damage during ischemia/reperfusion,” Free Radical Biology & Medicine, vol. 42, no. 10, pp. 1571–1578, 2007.

[87] A. Prange and D. Schaumlöffel, “Hyphenated techniques for the characterization and quantification of metallothionein isoforms,” Analytical and Bioanalytical Chemistry, vol. 373, no. 6, pp. 441–453, 2002.

[88] J. Szpunar, “Advances in analytical methodology for bioinorganic speciation analysis: metalloinorganic and heteroatom-tagged proteomics and metabolomics,” Analyst, vol. 130, no. 4, pp. 442–465, 2005.

[89] K. Polec-Pawlak, J. K. Abramski, O. Semenova, et al., “Platinum group metallogroup-protein binding studies by capillary electrophoresis—inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins,” Electrophoresis, vol. 27, no. 5–6, pp. 1128–1135, 2006.

[90] S. S. Aleksenko, C. G. Hartinger, O. Semenova, K. Meelich, A. R. Timerbaev, and B. K. Keppler, “Characterization of interactions between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis,” Journal of Chromatography A, vol. 1155, no. 2, pp. 218–221, 2007.

[91] A. V. Rudnev, S. S. Aleksenko, O. Semenova, C. G. Hartinger, A. R. Timerbaev, and B. K. Keppler, “Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method,” Journal of Separation Science, vol. 28, no. 2, pp. 121–127, 2005.

[92] K. Kim, S. Cho, J. H. Park, et al., “Surface plasmon resonance studies of the direct interaction between a drug/intestinal brush border membrane,” Pharmaceutical Research, vol. 21, no. 7, pp. 1233–1239, 2004.

[93] T. Y. Low, C. K. Leow, M. Salto-Tellez, and M. C. M. Chung, “A proteomic analysis of thioacetamide-induced hepatotoxicity and cirrhosis in rat livers,” Proteomics, vol. 4, no. 12, pp. 3960–3974, 2004.

[94] S. Steiner, L. Aicher, J. Raymacers, et al., “Cyclosporine A decreases the protein level of the calcium-binding protein calbindin-D 28 kDa in rat kidney,” Biochemical Pharmacology, vol. 51, no. 3, pp. 253–258, 1996.

[95] L. Aicher, D. Wahl, A. Arce, O. Grenet, and S. Steiner, “New insights into cyclosporine A nephrotoxicity by proteome analysis,” Electrophoresis, vol. 19, no. 11, pp. 1998–2003, 1998.

[96] A. Castagna, P. Antonioli, H. Astner, et al., “A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431,” Proteomics, vol. 4, no. 10, pp. 3246–3267, 2004.

[97] K. Le Moguen, H. Lincet, P. Marcelo, et al., “A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment,” Proteomics, vol. 7, no. 22, pp. 4090–4101, 2007.
K. Le Moguen, H. Lincet, E. Deslandes, et al., “Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10,” *Proteomics*, vol. 6, no. 19, pp. 5183–5192, 2006.

S. Gilbert, A. Loranger, N. Daigle, and N. Marceau, “Simple epithelium keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targeting modulation,” *Journal of Cell Biology*, vol. 154, no. 4, pp. 763–773, 2001.

Y. Wang, Q.-Y. He, S.-W. Tsao, Y.-H. Cheung, A. Wong, and J.-F. Chiu, “Cytokeratin 8 silencing in human nasopharyngeal carcinoma cells leads to cisplatin sensitization,” *Cancer Letters*, vol. 265, no. 2, pp. 188–196, 2008.

M. M. Gottesman, “Mechanisms of cancer drug resistance,” *Annual Review of Medicine*, vol. 53, pp. 615–627, 2002.

G. Hütter and P. Sinha, “Proteomics for studying cancer cells and the development of chemoresistance,” *Proteomics*, vol. 1, no. 10, pp. 1233–1248, 2001.

B. Sun, J. A. Ranish, A. G. Utley, et al., “Shotgun glycopeptide capture approach coupled with mass spectrometry for comprehensive glycoproteomics,” *Molecular & Cellular Proteomics*, vol. 6, no. 1, pp. 141–149, 2007.

J. J. Stewart, J. T. White, X. Yan, et al., “Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with miRNA expression levels,” *Molecular & Cellular Proteomics*, vol. 5, no. 3, pp. 433–443, 2006.

Y. Wang, Y. H. Cheung, Z. Yang, J.-F. Chiu, C.-M. Che, and Q.-Y. He, “Proteomic approach to study the cytotoxicity of dioscin (saponin),” *Proteomics*, vol. 6, no. 8, pp. 2422–2432, 2006.

L. Xie, G. Tsaprailis, and Q. M. Chen, “Proteomic identification of insulin-like growth factor-binding protein-6 induced by sublethal H2O2 stress from human diploid fibroblasts,” *Molecular & Cellular Proteomics*, vol. 4, no. 9, pp. 1273–1283, 2005.

J. Kanski, S. J. Hong, and C. Schöneich, “Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry,” *Journal of Biological Chemistry*, vol. 280, no. 25, pp. 24261–24266, 2005.

M. Colombini, “Voltage gating in the mitochondrial channel, VDAC,” *Journal of Membrane Biology*, vol. 111, no. 2, pp. 103–111, 1989.

P. Bernardi, K. M. Broekemeier, and D. R. Pfeiffer, “Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane,” *Journal of Bioenergetics and Biomembranes*, vol. 26, no. 5, pp. 509–517, 1994.

M. Zoratti and I. Szabo, “The mitochondrial permeability transition,” *Biochimica et Biophysica Acta*, vol. 1241, no. 2, pp. 139–176, 1995.

S. Shimizu, M. Narita, and Y. Tsuchimoto, “Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC,” *Nature*, vol. 399, pp. 483–487, 1999.

M. Madesh and G. Hajnóczy, “VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release,” *Journal of Cell Biology*, vol. 155, no. 6, pp. 1003–1015, 2001.

S. Shimizu, Y. Shinozawa, and Y. Tsuchimoto, “Bax and Bcl-x independently regulate apoptotic changes of yeast mitochondria that require VDAC but not adenine nucleotide translocator,” *Oncogene*, vol. 19, no. 38, pp. 4309–4318, 2000.

F. Schmidt, H. K. Hustoft, M. Strozynski, C. Dimmler, T. Rudel, and B. Thiede, “Quantitative proteome analysis of cisplatin-induced apoptotic Jurkat T cells by stable isotope labeling with amino acids in cell culture, SDS-PAGE, and LC-MALDI-TOF/TOF MS,” *Electrophoresis*, vol. 28, no. 23, pp. 4359–4368, 2007.